Sickle cell disease and cellular treatment

Category: Conditions & evidence · Editorial Review: Updated 20 October 2026 · 3 minute read

A disease of hemoglobin

Sickle cell disease is inherited and affects hemoglobin within red blood cells. Treatment aims to reduce complications and protect organs. Blood-forming stem cell transplantation can be considered for selected patients. Gene-modified treatments also involve a specialized cell collection and treatment pathway, but their mechanisms, eligibility and availability are different from a donor transplant.

The benefit-risk discussion

Ask how your history of pain episodes, stroke risk, lung problems, kidney function and previous treatment affects candidacy. A potentially curative approach can still carry serious short- and long-term risks. Fertility preservation, conditioning toxicity and the possibility of inadequate engraftment deserve explicit discussion. Do not interpret a successful individual story as a forecast for your own outcome.

Do not assume access in Korea

Approval in another country does not establish that the same product is authorized, funded or accessible at a Korean hospital. Obtain the exact treatment name, current local indication and responsible hospital service. A clinic advertising stem cells generally may not have any sickle cell transplantation or gene therapy program.

Documents and continuity

Bring genotype information, transfusion and antibody records, imaging, organ assessments and a list of current medicines. Ask how blood products will be sourced if needed and how pain care will continue during travel. A treatment decision should include a long-term monitoring plan with both the overseas center and the clinician who normally manages your disease.

Continue exploring

• Acute myeloid leukemia and transplantation
• Acute lymphoblastic leukemia and transplantation
• Multiple myeloma and autologous transplant
• Prepare your consultation checklist

Sources & further reading

• Primary patient information and research

Read alongside your treating specialist’s advice. Clinical eligibility, exact products and treatment plans require individual assessment.